Document:

Unassociated Document

    EXHIBIT
10.1

     

    [Translated
from the original Chinese version]

    

    [***] –
Confidential portions.  Certain information in this exhibit has been
omitted and filed separately with the Securities and Exchange Commission.
Confidential treatment has been requested with respect to the omitted
portions.

    

    Assignment
Contract

    

    Contract
Object: [***]

    Category:
[***]

    

    
      Assignor (hereinafter referred as Party A): Hainan
Zhonghe Peptide Drugs Research & Development Co.,
Ltd.
Address:
Free Trade Zone, No.168 Nanhai Avenue, Haikou City, Hainan Province,
China

    
      Legal
Representative: Zongzhen Zhou

    

    
      Reference:
Zongzhen Zhou

    

    
      Tell:
+86898 6680 2208   Fax: +86898 6680 2211

    

    
      Email:
Sunny@zhonghe.net

    

    

    Assignee
(hereinafter referred as Party B): Hainan Zhonghe Pharmaceutical Co.,
Ltd.

    
      Address:
Free Trade Zone, No.168 Nanhai Avenue, Haikou City, Hainan Province,
China

    

    
      Legal
Representative: Xueyun Cui

    

    
      Reference:
Zhuo Lin

    

    
      Tell:
+86898 6680 2833   Fax: +86898 6680 2833

    

    
      Email:
Lingel_2000@yahoo.com

    

    

    Date:
March 23, 2009

    Signed
at: Haikou City, Hainan Province

     

     

    
      
        
        

      

      
        
        

        
          

        

      

      
        
        

      

    

     

    In
accordance with “Contract Law of the People’s Republic of China”, “Provisions
for Drug Registration” issued by State Food and Drug Administration (herein
after referred as SFDA), PRC, both the assignor and the assignee (hereinafter
referred as “the Parties”) have, based on the real, fully express of their
wishes, through equal consultation, entered into the contract (hereinafter
referred as “the Contract”) concerning issues related to technical materials and
achievement, rights and interest, payment, default liabilities of the technology
as stated in this Contract, both Parties have agreed as follows:

    
      Article
1 Object of Assignment (Technological Secret)

      
        	
                1.1

              	
                Content
      of technology transferred to Party B by Party
A

              

      

      
        	
                 
      

              	
                Name
      of Object: [***] (hereinafter referred as “the Contract
      Object”)

              

      

      

      
        	
                 
      

              	
                Technical
      Specification and Parameter: Party A shall finish all researching and
      developing work (except for clinical trial) before applying for production
      in accordance with “Provisions for Drug Registration” issued by SFDA and
      related technical guidelines and requirements. Party A ensures to deliver
      all of its technical materials used for applying for clinical trial and
      product, manufacturing process of drug substance, as well as formula and
      manufacturing process of pharmaceutical preparations of the Contract
      Object to Party B, until Party B obtains the Drug Approval Number (Letter
      of Approval for Drug Registration) and successfully trial-manufactures 3
      batches of eligible products in a row
  independently.

              

      

      

      
        	
                 
      

              	
                Industrialization level of
      Technological Secret: Party A ensures that the formula and
      manufacturing process of the Contract Object reach industrialization level
      and ensures that the formula of pharmaceutical preparations and
      manufacturing process of drug substance and pharmaceutical preparations
      used for applying for drug registration are the same with those are
      entering into market.

              

      

      

      Technical Service and Technical
Guidance: Party A shall give the Party B’s personnel free technical
training to ensure Party B’s personnel master the formal manufacturing process
of the Contract Object; Party A shall provided free instruction to Party B’s
personnel to ensure Party B’s personnel manufacture 3 batches of the Contract
Object which meet the quality standards in a row.

      

      
        	
                1.2

              	
                New
      Medicine Certificate, Letter of Approval for Drug Registration, Drug
      Approval Number and all proprietary rights of the Contract Object shall be
      transferred to Party B exclusively.

              

      

      

      
        	
                1.3

              	
                Both
      Parties agree that the application of production to Center for Drug
      Evaluation of SFDA shall be under Party B’s
  name.

              

      

       

      
        
          
          

        

        
          
          

          
            

          

        

        
          
          

        

      

       

      Article
2 Obligations of Both Parties

      

      
        	
                2.1

              	
                Party
      B shall pay Party A assignment fee in conformity with the Contract’s
      term.

              

      

      

      
        	
                2.2

              	
                Party
      B has the obligation to cooperate Party A in applying for drug
      registration and clinical testing.

              

      

      

      
        	
                2.3

              	
                Party
      A ensures to provide Party B the whole, completed, up-to-requirement
      documentation including dossiers for registration application, original
      data of development, map and samples, etc. of the Contract Object in
      accordance with registration requirements within 60 days after signature
      of this Contract. Party A ensures the Contract Object pass the process
      performed by Hainan Medical Appliance Administration and SFDA including
      acceptance of drug registration, on-site inspection, review and approval
      for registration, clinical trial, and production
  approval.

              

      

      

      
        	
                2.4

              	
                Party
      A shall be responsible for applying for registration and answering all
      technical questions likely to be posed by SFDA’s Center for Drug
      Evaluation during process of application and ensures to complete relevant
      test and supplement new technical dossiers within the specified timeline
      without compensation till conform to registration
      requirements.

              

      

      

      
        	
                2.5

              	
                Party
      A ensures all dossiers for registration application, original data of
      development, map and samples conformed with the regulation of active
      Provisions for Drug Registration and relevant regulations, related
      technical guidelines and requirements as well. Party A ensures the
      authenticity, standardization, dependability and integrity of technical
      information delivered thereby.

              

      

      

      
        	
                2.6

              	
                Party
      A ensures the Contract Object having obtained Drug Clinical Trial Approval
      before the signing date of this
Contract.

              

      

      

      
        	
                2.7

              	
                Party
      A shall provide Party B free instruction in time to hand over
      manufacturing process of the Contract Object before and during Party A’s
      manufacturing samples for clinical trial and on-site examination of
      production for drug registration to ensure Party B’s ability of
      trial-manufacturing 3 batches of the Contract Object in a row. Party A has
      the responsibility to cooperate Party B in solving problems about formula
      and manufacturing process in production of Contract
  Object.

              

      

      

      
        	
                2.8

              	
                Party
      B shall, under Party A’s direction, manufacture samples for clinical trial
      and 3 batches of samples for registration inspection at Party A’s expense.
      Party B shall give Party A at least 10 day’s advance notice for Party A’s
      personnel to hand over the
technology.

              

      

      

      
        	
                2.9

              	
                Party
      B has the right to carry out further improvement on the Technology Secret
      after assignment, any new technological achievements with substantive or
      productive progress accomplished thus shall remain the property of Party
      B.

              

      

      

      
        	
                2.10

              	
                Party
      A shall provide Party B all technological dossiers of any further
      improvement or development of the Technology Secret in writing in a timely
      manner. All improvement on Technology Secret accomplished thereby shall
      remain property of Party B and may not transferred by Party A to any other
      party without the written approval of Party
B.

              

      

       

      
        
          
          

        

        
          
          

          
            

          

        

        
          
          

        

      

       

      
        	
                2.11

              	
                Party
      A ensures that the Technology Secret is practicable and reliable and does
      not encroach the third party’ legal rights. In case of accusation by third
      party of encroachment upon their legal right, Party A shall bear full
      responsibility for all consequences arisen therefrom and compensate for
      Party B’s economical losses.

              

      

      

      
        	
                2.12

              	
                Party
      A shall not, during the term of this Contract, apply for patent for the
      Technology Secret or make the Technology Secret public in other way
      without Party B’s written consent. Party A shall be responsible for
      preparation of the Contract related patent in time pursuant to developing
      progress of the Contract Object and delivery to Party B who shall be in
      charge of related application and expenses incurred thereby. Party B shall
      be applicant and patentee thereafter and Party A’s personnel inventors.
      Party B has the right to use the patent without compensation, however
      shall pay Party A’s inventors for preparation of the patent, the actual
      fee will be negotiated separately depending on content of patent
      declared.

              

      

      

      Article
3 Terms of Payment

      The total
assignment fee under this Contract is RMB 60 million paid in installments
according to project progress as below:

      

      
        	
                 
      

              	
                o

              	
                Eighty
      percent (80%) of total price, namely RMB 48 million shall be paid to Party
      A within 30 working days after obtaining Drug Clinical Trial Approval
      issued by SFDA.

              

      

      
        	
                 
      

              	
                o

              	
                Ten
      percent (10%) of total price, namely RMB 6 million shall be paid to Party
      A within 20 working days after filing a registration application to Center
      for Drug Evaluation of SFDA.

              

      

      
        	
                 
      

              	
                o

              	
                Ten
      percent (10%) of total price, namely RMB 6 million shall be paid to Party
      A within 20 working days after obtaining production approval (Drug
      Approval Number).

              

      

      

      Article
4 Default Clause

      
        	
                4.1

              	
                Either
      of the two Parties who fail to fulfill the Contract in according to the
      terms specified herein will be deemed break the Contract and shall take
      the breach responsibilities in below
manners:

              

      

      

      
        	
                 
      

              	
                o

              	
                If
      the Contract Object fails to get New Medicine Certificate or Drug Approval
      Number due to Party A’s reason (e.g. technology or patent violation, fails
      to hand over dossiers for registration application within the timeline
      specified by Contract, etc.), Party A shall return Party B entire already
      paid assignment fee and already paid registration inspection fee,
      evaluation and approval fee, clinical trial fee (subject to invoice)
      within 20 working days at one time, the Contract will automatically be
      terminated, the Contract Object shall be Party A ‘s property and Party B
      shall return all technical
materials.

              

      

      

      
        	
                 
      

              	
                o

              	
                If
      Party B fails to obtain Drug Approval Number due to Party B’s reason (e.g.
      fails to apply for registration within specified timeline, production
      conditions fails to meet required standards, etc.), Party A shall not bear
      the responsibility and is entitled to reserve fees already paid by Party
      B. The Contract will automatically be terminated, Party B may dispose the
      Contract Object by its own means.

              

      

      

      
        	
                 
      

              	
                o

              	
                Under
      the circumstance that Party A fails to finish and hand over the jobs
      specified in Clause 3, 4, Article 2 or other relative terms of this
      Contract, Party B is entitled to deduct a penalty equal to 0.01% of total
      price from unpaid assignment fee for each day of delay. If Party A fails
      to finish and hand over the above mentioned jobs within 4 months after
      specified timeline, Party B has the right to terminate the Contract, Party
      A shall return entire already paid fee by Party B within 20 working days
      and pay Party B overdue penalty.

              

      

       

      
        
          
          

        

        
          
          

          
            

          

        

        
          
          

        

      

       

      
        	
                 
      

              	
                o

              	
                Under
      the circumstance that Party B fails to pay the assignment fee within
      timeline specified by this Contract, it shall be charged a penalty equal
      to 0.01% of overdue amount for per day of
delay.

              

      

      

      
        	
                 
      

              	
                o

              	
                Party
      A shall keep secret certain contents limited by this Contract and shall
      not transfer the Technology Secret to any third party, otherwise shall
      return Party B entire already paid fee by Party B at one time and pay
      Party B a penalty equal to 5% of total assignment
  fee.

              

      

      

      
        	
                4.2 

              	
                The
      Parties shall consult whether to continue this Contract after the breaking
      party bear its default
responsibility.

              

      

       

      Article
5 Others

      
        

        
          
            	
                    5.1

                  	
                    

                      Any
      incapacity or unnecessary of executing this Contract due to force majeure
      is subject to negotiation between two Parties for
      dissolution.

                    

                  
	 	 
	

                    5.2

                  	

                    During
      the period of this Contract, Party A appoints Zongzhen Zhou as its project
      reference, Party B appoints Zhuo Lin as its project reference. References
      shall be responsible for:

                  
	 	 
	 	

                    1
      Keep in touch and resolve problems in
  time.

                  
	 	 
	 	

                    2
      Report the project progress.

                  
	 	 
	 	

                    Either
      of the two Parties who change reference shall make the other party known
      in writing, otherwise shall bear the responsibilities arisen therefrom and
      compensate the losses incurred.

                  
	 	 
	

                    5.3

                  	

                    Party
      A shall deliver technological materials of the Contract Object in both
      writing and soft copy.

                  
	 	 
	

                    5.4

                  	

                    Change
      of this Contract or amendment of article shall be done through negotiation
      between two Parties separately in written form and taken as
      appendices.

                  
	 	 
	

                    5.5

                  	

                    Both
      Parties must strictly voluntarily observe the terms of this Contract. Any
      outstanding issue not stipulated under this Contract shall be subject to
      negotiation between two Parties based on the principle of sincerity. In
      case of consultation or negotiation fails, appeal to people’s
      court.

                  
	 	 
	

                    5.6

                  	

                    This
      Contract is in quadruplicates, with each party hold two originals with
      equal legal validity.

                  
	 	 
	

                    5.7

                  	

                    This
      Contract comes into force on the date of signing and ceases to be effect
      till both Parties fulfill their
  responsibilities.

                  

          

        

      

      

      Party A:
Hainan Zhonghe Peptide Drugs Research & Development Co., Ltd.

      

      
        Legal
Representative:

      

       

      Party B:
Hainan Zhonghe Pharmaceutical Co., Ltd.

       

      Legal
Representative:Exhibit
10.1

    

    Consulting
Agreement

    

    This
Consulting Agreement (“Agreement”)
is made and entered into as of February 12, 2009, by WindTamer Corporation, a
New York corporation (the “Company”),
and Patricia Cole (“Consultant”).

    

    Recitals

    

    A.           The
Company is in its development stage as an independent developer of wind turbine
technology.

    

    B.           In
connection with its product development and commercialization efforts, the
Company wishes to utilize the services of Consultant, a licensed real estate
agent, to assist the Company in conducting searches for and locating, either for
purchase or lease, potential wind turbine sites that may be used by the Company
for construction and testing of new WindTamer prototypes, or by purchasers of
the Company's commercially produced turbines.

    

    C.           Consultant
has substantial experience and expertise in planning, directing and executing
commercial real estate searches that target strategic locations for
implementation of operational, manufacturing, product development and product
testing activities for development stage companies having objectives similar to
those of the Company with respect to commercialization and expansion, and
regularly provides consulting services and advice to companies that are in a
similar business stage, in connection with the formulation of business plans and
strategies and analysis of potential business locations and operating
procedures.

    

    D.           Consultant
and the Company have agreed on the terms and conditions pursuant to which
Consultant will be retained to provide consulting services.

    

    NOW, THEREFORE, the parties
agree as follows:

    

    
      	
              1. 

            	
              Appointment of
      Consultant

            

    

    

    1.1           Appointment;
Reporting.  By this Agreement, the Company appoints Consultant,
and Consultant accepts such appointment, to provide advice and consulting
services to the Company, in accordance with the terms and conditions of this
Agreement.

    

    1.2           Nature of Consulting
Services.  Consultant is retained to perform the following
consulting services (the “Services”):

    

    (a)           To
assist the Company in locating and developing potential manufacturing
sites;

    

    (b)           To
locate, and purchase or lease, on behalf of the Company, the most cost-effective
and productive sites upon which to erect new WindTamer prototypes and place
units purchased by the Company's commercial and residential customers;
and

     

    
      
         

      

      
         

        
          

        

      

      
         

      

    

     

    (c)           To
analyze and provide advice regarding the Company's strategic plan. The
Company may, at any time, request Consultant to make changes within the scope of
the Services or to perform extra work.

    

    1.3           Reporting. Consultant
shall provide a detailed, written report of Consultant's advice and analysis of
the foregoing matters, including specific recommendations for action to be taken
by the Company, and suggestions for implementation, together with such
supporting information and schedules as may be necessary to permit the Board to
evaluate such recommendations. In addition, Consultant shall provide interim
reports at the request of the Company.

    

    1.4           Hours of Consulting;
Personnel; Additional Consultants. It is expressly agreed that Consultant
will devote a minimum of twenty (20) hours per week during the term of this
Agreement.

    

    1.5           Status of
Consultant.  Consultant and the Company expressly agree that
Consultant is an independent contractor, and all Services performed under this
Agreement are performed by Consultant as an independent contractor. Consultant
shall control the time, manner, and place of performance of the
Services.

    

    1.6           Standard of
Performance.  Consultant shall perform her services and
complete her tasks to the Company’s satisfaction. Consultant shall comply with
all applicable federal, state, and local laws, ordinances, codes, and
regulations in performing the Services.

    

    1.7           Scheduling.

    

    A.           The
Consultant will develop and maintain a detailed schedule for completion of the
Services. The schedule will be a work plan showing activities to be performed
and their sequence. A preliminary schedule shall be submitted to the Company
within ten (10) days after execution of this Agreement for review and
establishment of the level of detail to be included.

    

    B.           The
Consultant will submit monthly progress data for the reporting period which will
include the percentage complete and actual start date and actual finish date for
all activities worked on by the Consultant during the period. Any changes in
delivery dates will be reported. Other information, such as actual hours
expended, will be furnished monthly, or as requested, by the Company. If
requested by the Company, update meetings will be held to discuss the results of
schedule analysis and necessary action to meet the requirements of the
schedule.

    

    
      	
              2. 

            	
              Term; Termination or
      Suspension.

            

    

    

    A.           Except
as provided below, this Agreement, and the Services to be performed under it,
shall commence on the date this Agreement is executed by both parties, and shall
continue thereafter through and including February 12, 2010.

    

    B.           The
Company may terminate this Agreement at-will without cause in its sole
discretion.

     

    
      
         

      

      
         

        
          

        

      

      
         

      

    

     

    C.           Upon
termination or cancellation of this Agreement, the Company shall have no
liability to Consultant except for charges for Services performed by Consultant
and accepted by the Company prior to termination.  The terms and
conditions in this Agreement that by their sense and context are intended to
survive the performance hereof by either or both parties hereunder shall so
survive the termination, cancellation, or completion of performance of this
Agreement.

    

    D.           Upon
completion of Consultant's services hereunder or at such other time as may be
requested by Company, Consultant shall return to Company all documents, records,
notebooks, including copies thereof, whether prepared by Consultant or others,
in Consultant's possession, and other Company property utilized by Consultant in
performing the Services.

    

    E.           The
Company reserves the right to suspend work on the Services, with or without
cause, in whole or in part, upon giving notice to Consultant. Consultant shall
resume the Services so suspended when directed to do so by the Company. If only
a portion of the work on the Services is suspended, Consultant shall be
compensated only for Services actually performed during such
suspension.

    

    
      	
              3. 

            	
              Compensation;
      Expenses.

            

    

    

    3.1           Consulting
Fees.  As the sole compensation for the performance of the
Services, Consultant shall be paid the following amounts:

    

    (a)            The
sum of five-thousand dollars ($5,000) per month, payable on the last day of each
full month during the term of this Agreement during which the Services are
performed.

    

    3.2           Reimbursement of
Expenses.  The Company shall reimburse Consultant for all
reasonable and necessary business and travel expenses actually incurred by
Consultant in performing the services, subject to receipt of a written request
for reimbursement, accompanied by appropriate supporting documentation.
Consultant may request reimbursement not more frequently than once every month
during the term of this Agreement.

    

    3.3           Withholding;
Benefits.  All fees payable to Consultant under this Agreement
shall be made in full, and without any withholding, deduction, or offset of any
state or federal withholding taxes, FICA, SDI, or income taxes, nor shall the
Company be obligated to pay any of Consultant's employees' taxes. Consultant
hereby covenants and agrees that it shall be solely responsible for all taxes,
withholding, FICA, SDI, and other similar items (both employee and employer
portions) with respect to all fees paid by the Company under this Agreement, and
agrees to indemnify and hold the Company harmless with respect to such taxes and
withholding. Neither Consultant nor Principal shall be eligible for, shall
participate in, or shall be entitled to compensation in lieu of any insurance,
benefit, retirement, or other plan or program provided by the Company to its
employees.

     

    
      
         

      

      
         

        
          

        

      

      
         

      

    

     

    4.           Confidentiality; Non-Solicitation;
Intellectual Property.  As a material inducement to the Company
to enter into this Agreement and pay the compensation set forth in Section 3,
the Consultant hereby expressly agrees to be bound by the following covenants,
terms and conditions:

    

    A.           During
the course of the Consultant's relationship with the Company or any of its
affiliates, the Consultant has had, and will have, access to Confidential
Information relating to the Company and its affiliates and their respective
suppliers, partners and customers. The Consultant agrees to keep secret and
retain in strictest confidence all of such Confidential Information, and will
not disclose, disseminate or use such information for the Consultant's own
advantage or for the advantage of any other person or entity other than the
Company in accordance with the terms of the Consultant's employment or
relationship with the Company.  In the event disclosure of any such
Confidential Information is required or purportedly required by law, the
Consultant will provide the Company with prompt notice of any such requirement
so that the Company may seek an appropriate protective order prior to
disclosure.

    

    B.           In
the event that the Consultant as part of his activities on behalf of the Company
generates, creates, authors or contributes to any invention, design, new
development, device, product, method or process (whether or not patentable or
reduced to practice or constituting Confidential Information), any copyrightable
work (whether or not constituting Confidential Information) or any other form of
Confidential Information relating directly or indirectly to the Company's
business (including anything that has occurred since the first date Consultant
provided services to the Company), the Consultant acknowledges that such
Intellectual Property is the exclusive property of the Company and hereby
assigns all right, title and interest in and to such Intellectual Property to
the Company.  Any copyrightable work prepared in whole or in part by
the Consultant is and will be deemed “a work made for hire” under Section 201(b)
of the 1976 Copyright Act, and the Company shall own all of the rights comprised
by the copyright therein.  The Consultant shall promptly and fully
disclose all Intellectual Property to the Company and shall cooperate with the
Company to protect the Company's interests in and rights to such Intellectual
Property (including, without limitation, providing reasonable assistance in
securing patent protection and copyright registrations and executing all
documents as reasonably requested by the Company, whether such requests occur
prior to or after termination of the Consultant's employment with the
Company).  Notwithstanding the date of this Agreement or anything else
herein to the contrary, the provisions of this Section 4 shall be deemed to be
effective as of and apply to all matters occurring since the first date
Consultant provided services to the Company.

    

    C.           As
requested by the Company from time to time for any reason, the Consultant shall
promptly deliver to the Company all copies and embodiments, in whatever form, of
all Confidential Information and Intellectual Property in the Consultant's
possession or within his control (including, but not limited to, written
records, notes, photographs, manuals, notebooks, documentation, program
listings, flow charts, magnetic media, disks, diskettes, tapes and all other
materials containing any Confidential Information or Intellectual Property)
irrespective of the location or form of such material and, if requested by the
Company, shall provide the Company with written confirmation that all such
materials have been delivered to the Company.

     

    D.           The
Consultant agrees that, for the period of this Agreement and for two years
thereafter, it will not directly or indirectly represent, be employed by,
consult for, or otherwise be associated with any other business engaged in wind
turbine technology.

     

    
      
         

      

      
         

        
          

        

      

      
         

      

    

     

    E.           The
Consultant acknowledges that in the event the Consultant violates any provisions
of this Section 4, in addition to its other rights and remedies, the Company
shall be entitled to injunctive relief without the necessity of proving actual
damages.  The Consultant further acknowledges that if any provision of
this Section 4 is held to be unenforceable, the court making such holding shall
have the power to modify such provision and in its modified form such provision
shall be enforced.

    

    F.           Without
in any way limiting the provisions of this Section 4, the Consultant further
acknowledges and agrees that the provisions of this Section 4 shall remain
applicable in accordance with their terms after the termination or cessation of
services to the Company or exercise or termination of the Option.

    

    G.           “Confidential
Information” means information or material proprietary to the Company or
designated as Confidential Information by Company and not generally known by
non-Company personnel, which the Consultant develops, or of which Consultant
obtains knowledge, or to which the Consultant may obtain access, through or as a
result of, the Consultant's relationship with the Company (including information
conceived, originated, discovered or developed in whole or in part by the
Consultant).  Confidential Information includes, but is not limited
to, the following types of information and other information of a similar nature
(whether or not reduced to writing): discoveries, ideas, concepts, software in
various stages of development, designs, drawings, specifications, techniques,
models, data, source code, object code, data structures, instruction sets,
documentation, diagrams, flow charts, research, development, training methods,
training manuals, processes, procedures, “know-how”, marketing techniques and
materials, marketing and development plans, customer names and other information
related to customers, price lists, pricing policies and financial
information.  Confidential information also includes any information
described above which the Company obtains from other entities and which the
Company treats as proprietary or designates as Confidential Information, whether
or not owned or developed by the Company.  Notwithstanding the
foregoing, information publicly known that is generally employed by the trade at
or after the time Consultant first learns of such information, or generic
information or knowledge which associate would have learned in the course of
similar employment or work elsewhere in the trade, shall not be deemed part of
the confidential information.

    

    H.           “Intellectual
Property” shall mean those forms of authorship (as understood from Title 17 of
the United States Code), invention (as understood by Title 35 of the United
States Code) and identification (as understood from Title 15 of the United
States Code Section 1051 et seq., trademarks and service marks) and such other
forms of property rights in ideas, “know how,” inventions, discoveries, or in
their physical embodiments as shall related to or involve the Company's business
or any of its products, services or strategies.

     

    
      
         

      

      
         

        
          

        

      

      
         

      

    

     

    
      	
              5. 

            	
              Miscellaneous.

            

    

    

    5.1           Entire
Agreement.  This Agreement and the Company’s 2008 Equity
Incentive Plan, constitute the entire understanding between the parties, and
supersedes all prior agreements and negotiations, whether oral or written. There
are no other agreements between the parties, except as set forth in this
Agreement. No supplement, modification, waiver, or termination of this Agreement
shall be binding unless in writing and executed by all parties to this
Agreement.

    

    5.2           Assignment; Binding
Effect.  Neither this Agreement nor any rights, benefits, or
obligations under it may be assigned by any party to this Agreement without the
prior express written consent of the other party. Subject to the foregoing, this
Agreement shall inure to the benefit of and be binding upon all of the parties
to this Agreement and their respective executors, administrators, successors,
and permitted assigns.

    

    5.3           Severability.  In
the event any of the provisions of this Agreement are found by a court of
competent jurisdiction to be invalid, illegal, or unenforceable, the validity,
legality, and enforceability of the remaining provisions shall not be
affected.

    

    5.4           Governing
Law.  This Agreement shall be governed by and construed in
accordance with the laws of the State of New York.

    

    5.5           Counterparts.  This
Agreement may be executed in two or more counterparts, which shall together
constitute one and the same agreement.

    

    IN WITNESS WHEREOF, the
parties have executed this Agreement as of the date first written
above.

    

    FUTURE
ENERGY SOLUTIONS, INC.

    

    /s/ Gerald E.
Brock                                         

    By:
Gerald E. Brock

    Its:
President and CEO

    

    CONSULTANT

    

      /s/ Patricia
Cole____________________

    Patricia
Cole

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00157-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00157-of-00352.parquet"}]]